Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020205537 - COVALENT MODIFICATION AND CONTROLLED DELIVERY OF MU OPIOID RECEPTOR ANTAGONISTS

Publication Number WO/2020/205537
Publication Date 08.10.2020
International Application No. PCT/US2020/025266
International Filing Date 27.03.2020
IPC
A61K 31/439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4745 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/4748 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4748forming part of bridged ring systems
Applicants
  • ALLEGHENY SINGER RESEARCH INSTITUTE [US]/[US]
Inventors
  • AVERICK, Saadyah
  • KASSICK, Andrew
Agents
  • GLYNN, Christopher, W.
  • SINGER, James, M.
  • TERRIL, Brienne, S.
  • AGARWAL, Gunjan
Priority Data
62/826,43829.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COVALENT MODIFICATION AND CONTROLLED DELIVERY OF MU OPIOID RECEPTOR ANTAGONISTS
(FR) MODIFICATION COVALENTE ET ADMINISTRATION CONTRÔLÉE D'ANTAGONISTES DES RÉCEPTEURS OPIOÏDES DE TYPE MU
Abstract
(EN)
Polymer conjugates comprising a hydrophobic biodegradable polymer covalently attached to a mu opioid receptor (MOR) antagonist are described. Biodegradable covalent nanoparticles comprising the hydrophobic biodegradable polymer covalently attached to a MOR antagonist are provided as a vehicle for the sustained delivery of the MOR antagonist. The described MOR antagonist delivery system may be used to more effectively prevent or overcome the toxic effects of synthetic opioids.
(FR)
L'invention concerne des conjugués polymères comprenant un polymère biodégradable hydrophobe attaché de manière covalente à un antagoniste des récepteurs opioïdes de type mu (MOR). Des nanoparticules covalentes biodégradables comprenant le polymère biodégradable hydrophobe attaché de manière covalente à l'antagoniste des MOR sont fournies en tant que véhicule d'administration prolongée de l'antagoniste des MOR. Le système d'administration de l'antagoniste des MOR selon l'invention peut être utilisé pour prévenir ou contrer plus efficacement les effets toxiques des opioïdes synthétiques.
Latest bibliographic data on file with the International Bureau